Von Willebrand Factor Levels in Patients With Liver Cirrhosis and Portal Hypertension

NCT06694090 | Not Yet Recruiting

• 1 other identifier: Von willebrand factor levels
• Study Type: observational
• Target: 67
• Locations: 0 countries
• Sites: N/A

Brief Summary

Verify Von willebrand factor role in patients with liver cirrhosis and portal hypertension

Conditions

Liver Cirrhosis; Portal Hypertension

Keywords

Von willebrand factor; Liver cirrhosis; Portal hypertension

Outcome Measures

Primary Outcomes (1)

• Verify Von willebrand factor role in patients with liver cirrhosis and portal hypertension by using VWF-Ag concentation and fibroscan

  Baseline

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients aged 18-65 years with all stages of liver cirrhosis (compensated and decompensated)

You may qualify if:

• adult patient \>18 years
• both sex male and female
• all stages of liver cirrhosis (compensated and decompensated)

You may not qualify if:

• acute liver disease
• any hereditary or acquired diseases that affect VWF level.
• sepsis and infections (including spontaneous bacterial peritonitis), patients with any infectious symptoms at the time of study (increasing VWF Ag levels).
• active extrahepatic malignancies.
• previous liver transplantation.
• any medication affect VWF level.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (15)

• Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, Bertet J, Couzigou P, de Ledinghen V. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006 Mar;55(3):403-8. doi: 10.1136/gut.2005.069153. Epub 2005 Jul 14.

  PMID: 16020491 RESULT

• Curakova Ristovska E, Genadieva-Dimitrova M, Caloska-Ivanova V, Misevski J. Von-Willebrand factor as a predictor of three-month mortality in patients with liver cirrhosis compared to MELD score. Acta Gastroenterol Belg. 2019 Oct-Dec;82(4):487-493.

  PMID: 31950803 RESULT

• Hametner S, Ferlitsch A, Ferlitsch M, Etschmaier A, Schofl R, Ziachehabi A, Maieron A. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test. PLoS One. 2016 Feb 19;11(2):e0149230. doi: 10.1371/journal.pone.0149230. eCollection 2016.

  PMID: 26895398 RESULT

• van den Boom BP, Stamouli M, Timon J, Bernal W, Blasi A, Adelmeijer J, Fernandez J, Lisman T, Patel VC. Von Willebrand factor is an independent predictor of short-term mortality in acutely ill patients with cirrhosis. Liver Int. 2023 Dec;43(12):2752-2761. doi: 10.1111/liv.15728. Epub 2023 Sep 16.

  PMID: 37715606 RESULT

• Elhence A, Shalimar. Von Willebrand Factor as a Biomarker for Liver Disease - An Update. J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1047-1060. doi: 10.1016/j.jceh.2023.05.016. Epub 2023 Jun 2.

  PMID: 37975050 RESULT

• Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006 Jul;44(1):53-61. doi: 10.1002/hep.21231.

  PMID: 16799972 RESULT

• Pomej K, Scheiner B, Balcar L, Nussbaumer RJ, Weinzierl J, Paternostro R, Simbrunner B, Bauer D, Pereyra D, Starlinger P, Stattermayer AF, Pinter M, Trauner M, Quehenberger P, Reiberger T, Mandorfer M. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease. Dig Liver Dis. 2022 Oct;54(10):1376-1384. doi: 10.1016/j.dld.2022.06.010. Epub 2022 Jul 22.

  PMID: 35871985 RESULT

• Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, Ay C, Quehenberger P, Fritzer-Szekeres M, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferlitsch A; Vienna Hepatic Hemodynamic Lab. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther. 2018 Apr;47(7):980-988. doi: 10.1111/apt.14522. Epub 2018 Jan 29.

  PMID: 29377193 RESULT

• Mandorfer M, Hernandez-Gea V, Garcia-Pagan JC, Reiberger T. Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. Semin Liver Dis. 2020 Aug;40(3):240-255. doi: 10.1055/s-0040-1708806. Epub 2020 Jun 18.

  PMID: 32557480 RESULT

• Carnevale R, Raparelli V, Nocella C, Bartimoccia S, Novo M, Severino A, De Falco E, Cammisotto V, Pasquale C, Crescioli C, Scavalli AS, Riggio O, Basili S, Violi F. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. J Hepatol. 2017 Nov;67(5):950-956. doi: 10.1016/j.jhep.2017.07.002. Epub 2017 Jul 14.

  PMID: 28716745 RESULT

• Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, Violi F. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology. 1996 Jun;23(6):1377-83. doi: 10.1002/hep.510230613.

  PMID: 8675154 RESULT

• van der Vorm LN, Remijn JA, de Laat B, Huskens D. Effects of Plasmin on von Willebrand Factor and Platelets: A Narrative Review. TH Open. 2018 Jun 7;2(2):e218-e228. doi: 10.1055/s-0038-1660505. eCollection 2018 Apr.

  PMID: 31249945 RESULT

• Garcia-Pagan JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol. 2012 Aug;57(2):458-61. doi: 10.1016/j.jhep.2012.03.007. Epub 2012 Apr 12. No abstract available.

  PMID: 22504334 RESULT

• Mandorfer M, Simbrunner B. Prevention of First Decompensation in Advanced Chronic Liver Disease. Clin Liver Dis. 2021 May;25(2):291-310. doi: 10.1016/j.cld.2021.01.003. Epub 2021 Mar 10.

  PMID: 33838851 RESULT

• Yilmaz VT, Dincer D, Avci AB, Cetinkaya R. Significant Association between Serum Levels of Von Willebrand Factor (vWF) Antigen with Stages of Cirrhosis. Eurasian J Med. 2015 Feb;47(1):21-5. doi: 10.5152/eajm.2014.0016.

  PMID: 25745341 RESULT

MeSH Terms

Conditions

Liver Cirrhosis; Hypertension, Portal

Condition Hierarchy (Ancestors)

Liver Diseases; Digestive System Diseases; Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Kerolos A Sameh, Resident

  Assiut University

  PRINCIPAL INVESTIGATOR

• Mohamed A Ramadan, Lecturer

  Assiut University

  STUDY DIRECTOR

• Abdelhamid A Mohamed, Lecturer

  Assiut University

  STUDY DIRECTOR

Central Study Contacts

Kerolos A Sameh, Resident

CONTACT

01280978047; kerosameh752@gmail.com

Mohamed A Ramadan, Lecturer

CONTACT

01097510010; drmuhamedramadan@yahoo.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Target Duration: 20 Days
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident doctor

Study Record Dates

• First Submitted: November 14, 2024
• First Posted: November 19, 2024
• Study Start: November 15, 2024
• Primary Completion: November 15, 2025
• Study Completion: December 15, 2025
• Last Updated: November 19, 2024

Record last verified: 2024-11